A
Archon Biosciences
Creates computationally designed proteins to target and treat diseases that current methods cannot
About Archon Biosciences
Archon Biosciences is a biotechnology firm that emerged from stealth in October 2024 with $20 million in seed financing to develop its proprietary Antibody Cages (AbCs). Founded in 2023, the company is a spinout from the University of Washington's Institute for Protein Design (IPD), leveraging technology developed in the lab of Nobel laureate Dr. David Baker, who is also a co-founder. The other co-founders are CEO James Lazarovits, CTO George Ueda, and Lance Stewart. Lazarovits holds a Ph.D. in nanotechnology engineering and was a research faculty member at the IPD, while Ueda spent over a decade at the IPD under Dr. Baker's mentorship. Their research, which formed the basis for Archon, was initially published in 2021 and received over $7 million in grant funding prior to the seed round.
The company's core focus is on a novel class of biologics called Antibody Cages, which are designed to overcome the limitations of traditional antibody therapeutics. Archon utilizes computational protein design and generative AI to create these AbCs, which are new protein structures that combine with existing antibodies. This approach allows for precise control over the geometric structure of the antibody, which in turn influences how it is distributed in the body and how it engages with cellular targets. The key innovation lies in modifying the antibody's structure without altering its amino acid sequence, viewing it as a "bolt-on solution" to enhance its properties. This method aims to create more effective and safer therapeutics by improving target engagement and minimizing off-target effects, potentially rescuing drugs that previously failed in clinical trials due to efficacy issues.
Archon's business model revolves around developing a proprietary platform that can rapidly design, manufacture, and test new AbC candidates for various diseases, with an initial focus on oncology. The technology is designed to be a modular platform, allowing for the efficient creation of different drugs for diverse applications. The company serves the biopharmaceutical market by aiming to develop its own pipeline of drug candidates while also being open to partnerships with larger pharmaceutical companies. By creating a platform that interfaces with the industry-standard antibody format, Archon seeks to establish a new gold standard in biologic drug development. The company has stated its first targets are conditions without currently approved antibody treatments and is pursuing acute, not chronic, therapies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2023
- Headquarters
- Seattle, United States
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 74.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Antibodies, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEED✓Equity / VC | Oct 2024 | $20M | $80M | Alexandria Venture Investments · DUMAC · Cornucopian Capital · WRF Capital | ↗ |
| SPINOUT✓Other financing | Jan 2023 | $0 | — | University of Washington | — |
Growth signals
Latest recorded traffic for Archon Biosciences is 2.1K monthly website visits, down 34.4% over the last three months. Archon Biosciences's team declined 3.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Archon Biosciences in the Seattle ecosystem
The Archon Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed7 investors entered at this stage
Madrona Venture Group
Alexandria Venture Investments
DUMAC
Cornucopian Capital
WRF Capital
Sahsen Ventures
Pack Ventures
Other known investors1 additional known investor
University of Washington
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Archon Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Archon Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









